The Petrochemical Squeeze on Everyday Essentials

The escalating conflict in the Middle East is causing major swings in global energy and petrochemical markets, directly affecting Karex Bhd.'s costs. Soaring crude oil and natural gas prices are raising the cost of chemical compounds needed for condoms. Since January, prices for silicone oil have jumped around 30%, nitrile latex has doubled, and natural rubber is up by a third. These rising costs mean Karex's overall production expenses have increased by an estimated 25% to 30%. CEO Goh Miah Kiat also noted higher costs for condom wrappers and lubricants, adding to the financial pressure. Karex's reliance on petrochemicals from the Middle East makes it vulnerable to regional instability.

Demand Remains Strong, But Margins Face Pressure

Even with upcoming price increases, Karex expects condom demand to stay strong. CEO Goh Miah Kiat called the market 'inflation-proof,' suggesting consumer need might even rise in tough economic times. This strong demand contrasts with Karex's current financial results. The company reported a trailing twelve months (TTM) Earnings Per Share (EPS) of -0.002 MYR, showing a loss. Its TTM net income was -1.51 million MYR as of April 2026, with a negative P/E ratio due to losses. While its higher-margin commercial and Original Brand Manufacturing (OBM) segments can achieve gross profit margins of 20%-50%+, overall financial health is strained by rising input costs. Karex has two to three months of raw materials secured, but future supply remains uncertain if the conflict continues.

Competitive Arena and Valuation Concerns

Karex is the world's largest condom manufacturer by volume, producing about five billion units annually and holding roughly 20% of the global market share. Competitors include giants like Reckitt Benckiser (Durex) and Church & Dwight (Trojan), plus Okamoto Industries and Lifestyles Healthcare. Despite its size, Karex has lagged its industry and the broader Malaysian market over the past year. Its valuation is high, with a normalized P/E ratio of 121.46 and a TTM P/E of 179.3x. This is far above the consumer staples sector average of about 10.8x. This premium is hard to justify given its current losses and rising costs, suggesting potential downside. Analysts hold a mixed view, with a consensus 'Neutral' rating and recent price target cuts of up to 22% to RM0.61.

Key Risks for Karex

Karex faces significant risks. Its heavy reliance on petrochemical inputs, sensitive to Middle East instability, creates supply chain vulnerability. The company's current negative EPS and TTM net loss show financial fragility, making it harder to absorb prolonged cost increases than competitors with stronger finances. While Karex leads in production volume, brands like Durex dominate market revenue, highlighting intense competition beyond manufacturing scale. Strict regulatory requirements for medical products also limit the ability to easily find substitute materials for key components. The company's stock has weakened, underperforming its sector and the broader market. Analyst price target reductions also signal investor concern about its ability to manage these challenges and stay profitable amid rising costs and supply uncertainties.

Analyst View and Outlook

Analysts hold a neutral stance on Karex, weighing its market leadership in a resilient sector against immediate operational and financial challenges. The company's shift towards higher-margin OBM segments could improve profitability. However, the near-term outlook depends on how long the Middle East conflict lasts and its effect on petrochemical prices and supply. For Karex to turn its production volume into lasting financial success, managing these volatile conditions is crucial.